Pharmacotherapy for Pediatric Convulsive Status Epilepticus

Area of Science:

• Neurology
• Neuroscience
• Pediatric Emergency Medicine

Background:

• Convulsive status epilepticus (CSE) is a frequent pediatric neurological emergency.
• Pathophysiology involves impaired gamma-aminobutyric acid (GABA) inhibition and altered AMPA/NMDA receptor trafficking.
• These receptor dynamics contribute to prolonged and refractory SE (RSE).

Purpose of the Study:

• To review current understanding and treatment strategies for CSE.
• To highlight the evolving practice of early benzodiazepine (BZD) and non-BZD anti-seizure medication (ASM) administration.
• To discuss management of refractory SE (RSE) and future therapeutic considerations.

Main Methods:

• Literature review of CSE pathophysiology and treatment guidelines.
• Analysis of current clinical practice trends in SE management.
• Discussion of emerging therapeutic targets and polytherapy strategies.

Main Results:

• Rapid internalization of GABA_A receptors and synaptic membrane translocation of AMPA/NMDA receptors contribute to CSE.
• Early BZD administration and prompt escalation to non-BZD ASMs (valproate, fosphenytoin, levetiracetam) are recommended.
• Refractory SE (RSE) necessitates continuous EEG monitoring and titration of infusions, alongside etiological workup and immunotherapy.

Conclusions:

• Timely and aggressive treatment of CSE, including early ASM use, is critical.
• Management of RSE requires intensive care with EEG guidance.
• Future research should focus on accelerated diagnosis, targeted polytherapy, and understanding epileptogenesis mechanisms.